Compounds advantageous in the treatment of central nervous system diseases and disorders
申请人:AurimMed Pharma, Inc.
公开号:US10793515B2
公开(公告)日:2020-10-06
A series of novel amides showing broad pharmaceutical activity. Compounds described herein are effective as anticonvulsants, chemical countermeasures, and analgesics. Such compounds also show, neuroprotective/neuroreparative effects and activity against spinal muscular atrophy. Such pharmaceutically active compounds show utility in the treatment of central nervous system (“CNS”) diseases and disorders, such as anxiety, depression, insomnia, migraine headaches, schizophrenia, neurodegenerative diseases (e.g., Parkinson's disease, Alzheimer's, ALS, and Huntington's disease) spasticity, and bipolar disorder. Furthermore, such compounds may additionally find utility as analgesics (e.g., for the treatment of chronic or neuropathic pain) and as neuroprotective agents useful in the treatment of stroke(s), and/or traumatic brain and/or spinal cord injuries.
一系列新型酰胺具有广泛的药物活性。本文所述化合物可作为抗惊厥剂、化学对策和镇痛剂。这些化合物还具有神经保护/神经恢复作用,并对脊髓性肌肉萎缩具有活性。这类药物活性化合物可用于治疗中枢神经系统(CNS)疾病和失调,如焦虑症、抑郁症、失眠症、偏头痛、精神分裂症、神经退行性疾病(如帕金森氏病、阿尔茨海默氏症、渐冻人症和亨廷顿氏病)、痉挛症和躁狂症。此外,这类化合物还可作为镇痛剂(如治疗慢性疼痛或神经性疼痛)和神经保护剂用于治疗中风和/或创伤性脑损伤和/或脊髓损伤。